Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

SK Life Science, Inc.

Home Clinical Trial Sponsors and OrganizationsSK Life Science, Inc.

SK Life Science, Inc.

ACTIVE

461 From Rd FL 5, 新泽西州卑尔根县, New Jersey, United Stateswww.sklifescienceinc.comSubsidiary101–250 employeesEstablished: 2002-01-01

Part of SK Biopharmaceuticals Co., Ltd.

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

Clinical Trials

85

33 active

Approvals

4

Total approvals

Agencies

2

Regulatory bodies

Founded

2002

Overview

Trial Phase Distribution

Phase

Trials

Share

Phase 1

48

56.5%

Phase 3

17

20.0%

Phase 2

16

18.8%

Phase 4

1

1.2%

Trial Status Distribution

Active, not recruiting

33

38.8%

Approved For Marketing

1

1.2%

Completed

35

41.2%

Recruiting

13

15.3%

Terminated

3

3.5%

Clinical Trials

Trials sponsored by this organization (85)

SKL35501 With SKL35502 Imaging in Adults With NTSR1 Positive Advanced Solid Tumors

Aug 2026100 participants

Open-label Study of Cenobamate Monotherapy in Adult Subjects With Newly Diagnosed or Recurrent Partial-Onset Epilepsy

Active, not recruiting

Oct 202449 participants

A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Cenobamate Adjunctive Therapy in Subjects with Primary Generalized Tonic-Clonic Seizures

Jun 2024172 participants

A clinical study to evaluate safety and efficacy of Caribasmate

May 2024242 participants

A Multicenter Open-label Extension Study to Evaluate the Long-term Safety of Cenobamate Adjunctive Therapy in Subjects with Primary Generalized Tonic-Clonic Seizures

Apr 2024131 participants

Open-Label Safety and Efficacy Study of Cenobamate (YKP3089) in Children with Partial-onset (Focal) Seizures

Mar 2024180 participants

A clinical study to evaluate safety and efficacy of Caribasmate

Active, not recruiting

Feb 2023252 participants

A clinical study to evaluate safety and efficacy of Caribasmate

Active, not recruiting

Jan 2023252 participants

Page 1 of 11

Approvals

Approvals by Agency

NMPA

National Medical Products Administration

2

Approvals

FDA

Food and Drug Administration

2

Approvals

Recent Approvals

Cenobamate Tablets

Cenobamate Tablets

News

No news articles found

On this page

Overview
Clinical Trials85
Approvals4
News

Back to Organizations